Return to the CBW Resource homepage.
CB Warfare and Defenses
Jump to:
U.S. Force Protection |
Anthrax Vaccine Program |
CBW Defense
U.S. FORCE
PROTECTION
- Case Narrative:
U.S. Demolition Operations at Khamisiyah
Office of the Special
Assistant for Gulf War Illnesses, December 5, 2000
- Case
Narrative: The Cement Factory
Final Report, Office of the Special
Asst. to the Deputy Secretary of Defense for Gulf War Illnesses, August
4, 2000
- Intelligence
Related to Possible Sources of Biological Agent Exposure During the
Persian Gulf War
Office of the Special Assistant to the Director
of Central Intelligence for Persian Gulf War Illnesses, August 2000
- Case Narrative:
Possible Mustard Release at Ukhaydir Ammunition Storage
Depot
Office of the Special Assistant to the Director of Central
Intelligence for Persian Gulf War Illnesses, July 27, 2000
- Case Narrative:
Possible Chemical Agent on Scud Missile Sample
Final Report,
Office of the Special Asst. to the Deputy Secretary of Defense for Gulf
War Illnesses, July 25, 2000
- Combating
Terrorism: Action Taken But Considerable Risks Remain for Forces
Overseas
[GAO/NSIAD-00-181] July 19, 2000
- Force
Protection: Current Individual Protective Equipment
Hearing
before the House Subcommittee on National Security, Veterans' Affairs
and International Relations, June 21, 2000
Statement
of Rep. Christopher Shays, Chairman
Statement
of Donald Mancuso, Deputy Inspector General, U.S. Dept. of
Defense
Statement
of Brigadier Gen. Daniel G. Mongeon, Commander, Defense Supply
Center, Philadelphia
Statement
of Robert Kinney, Director, Individual Protection Directorate,
Natick Soldier Center, U.S. Army Soldier and Biological Chemical Command
- Proceedings
of the World-Wide Chemical Conference
National Defense Industries
Assoc., June 19-20, 2000, Ft. Leonard Wood, MO
- DoD
Chemical and Biological Defense Program: Management and
Oversight
Hearing before the House Subcommittee on National
Security, Veterans' Affairs and International Relations, May 24,
2000
Statement
of Rep. Christopher Shays, Chairman
Statement
of Kwai-Cheung Chan, Director, Special Studies and Evaluation Group,
General Accounting Office
Statement
of Dr. Anna Johnson-Winegar, Depty Assistant to the Secretary of
Defense for Chemical/Biological Defense
- Chemical and
Biological Defense Annual Report to Congress
Department of
Defense, March 2000
(Adobe Acrobat required)
- A
Review of the Scientific Literature as it Pertains to Gulf War
Illnesses
Vol. 5: Chemical and Biological Warfare Agents, William
S. Augerson, MR-1018/5-OSD (2000), National Defense Research
Institute/RAND
- Joint Service
Chemical & Biological Defense Program
FY2000-FY2001 Overview,
Office of Counterproliferation and Chemical and Biological Defense
Programs
- Nuclear Biological Chemical Defense Annual Report to
Congress
Office of Counterproliferation and Chemical and Biological
Defense Programs
2000
1999
1998
1997
- Counterproliferation Program Review Committee Annual Report to
Congress
Office of Counterproliferation and Chemical and Biological
Defense Programs
2000
1999
1998
1997
1996
1995
1994
- Chemical
and Biological Defense: Observations on Nonmedical Chemical and
Biological R&D Programs
GAO Testimony (GAO/T-NSIAD-00-130),
March 22, 2000
(Adobe Acrobat required for GAO documents)
- Annual Reports of the Office of the Special
Assistant to the Deputy Secretary of Defense for Gulf War
Illnesses
November
1998-1999
November 1996-1997
- Chemical
and Biological Defense: Observations on Actions Taken to Protect
Military Forces
GAO Report (GAO/T-NSIAD-00-49), October 20, 1999
- Chemical
and Biological Defense: Coordination of Nonmedical Chemical and
Biological R&D Programs
GAO Letter Report (GAO/NSIAD-99-160),
August 16, 1999
- Chemical
and Biological Defense: Program Planning and Evaluation Should Follow
Results Act Framework
GAO Letter Report (GAO/NSIAD-99-159),
August 16, 1999
- Chemical
and Biological Defense: DOD's Evaluation of Improved Garment
Materials
(GAO/NSIAD-98-214) August 18, 1998
- Vaccines
in Civilian Defense Against Bioterrorism
Philip K. Russell,
Journal of Emerging Infectious Diseases, Vol. 5, No. 4, July -
August 1999
- Vaccines,
Pharmaceutical Products, and Bioterrorism: Challenges for the U.S. Food
and Drug Administration
Kathryn C. Zoon, Journal of Emerging
Infectious Diseases, Vol. 5, No. 4, July - August 1999
- Biological
Warfare Force Protection
Information Paper, Dept. of Defense,
June 1998
- Chemical
and Biological Defense: Observations on DOD's Plans To Protect U.S.
Forces
GAO Testimony (GAO/T-NSIAD-98-83), April 17, 1998
- Report of the
Panel Reviewing Analysis of the Khamisiyah Pit Release of Nerve Agent,
March 1991
Summary of Findings, Office of the Special Asst. to
the Deputy Secretary of Defense for Gulf War Illnesses, July 1997
- Statement by Dr.
Bernard Rostker, Special Asst. to the Deputy Secretary of Defense
for Gulf War Illnesses, Before the Senate Veterans' Affairs Committee,
January 29, 1997
- Chemical
and Biological Defense: Emphasis Remains Insufficient to Resolve
Continuing Problems
GAO Testimony (GAO/T-NSIAD-96-154), May 1,
1996
- Chemical
and Biological Defense: Emphasis Remains Insufficient to Resolve
Continuing Problems
GAO Testimony (GAO/T-NSIAD-96-123), March 12,
1996
- Marine Corps
NBC Defense in Southwest Asia
"The Manley Report, " Marine Corps
Research Center Research Paper #92-0009, Captain T.F. Manley, July 1991
(de-classified September 15, 1997)
- US Army Chemical
School (USACMLS)
- Office of
the Project Manager for the NBC Defense Systems, "The Edgewood
Enterprise," U.S. Army
- Program Director for
Biological Defense Systems, U.S. Army
Includes information on the
Biological
Integrated Detection System (BIDS)
- Defense Threat
Reduction Agency (DTRA), Chemical and Biological Defense
- Program
Director for Biological Defense Systems (PD-BIO), U.S. Dept. of
Defense
Back to Top of Page
ANTHRAX VACCINE PROGRAM
- The
Anthrax Vaccine Immunization Program - What Have We Learned?
Hearing Before the House Committee on Government Reform, October 3,
2000
- The
Anthrax Vaccine Immunization Program - What Have We Learned? Part
Two
Hearing Before the House Committee on Government Reform,
October 11, 2000
- Department
of Defense Management of the Anthrax Vaccine Immunization Program
Hearing Before the House Military Personnel Subcommittee, July 13,
2000
Honorable
Rudy de Leon, Deputy Secretary of Defense
Statement
by Kathryn C. Zoon, Ph.D., Director, Center for Biologic Evaluation
and Research (CBER), U.S. Food and Drug Administration
Statement
by April G. Stephenson, Defense Contract Audit Agency
Statement
by Fuad El-Hibri, Chief Executive Officer, BioPort Corporation
- Contract
Management: DOD's Anthrax Vaccine Manufacturer Will Continue to Need
Financial Assistance , GAO Testimony GAO/T-NSIAD-00-140, April 14,
2000
- Medical
Readiness: DoD Continues to Face Challenges in Implementing its Anthrax
Vaccine Immunization Program
GAO Report GAO/T-NSIAD-00-157, April
13, 2000
- Unproven
Force Protection
Oversight report of the House Subcommittee on
National Security, Veterans Affairs and International Relations,
February 17, 2000
Medical
Readiness: DOD Faces Challenges in Implementing Its Anthrax Vaccine
Immunization Program
GAO Letter Report GAO/NSIAD-00-36, October
22, 1999
- Anthrax
Vaccine: Safety and Efficacy Issues, GAO Testimony
GAO/T-NSIAD-00-48, October 12, 1999
- Defense
Vaccines: Force Protection or False Security?
Hearing Before the
House Committee on Government Reform, October 12, 1999
Opening
Statement by Chairman Dan Burton
Statement
by Sue Bailey, M.D., Assistant Secretary for Health Affairs, Dept.
of Defense
Statement
by Cedric E. Dumont, M.D., Medical Director, Office of Medical
Services, Department of State
Statement
by Kathryn C. Zoon, Ph.D., Director, Center for Biologics,
Evaluation and Research, Food and Drug Administration
Statement
by William J. Crowe Jr. (Adm, USN Ret.), Former Chairman, Joint
Chiefs of Staff
Statement
by Dr. Jack Melling, Biologics Development Center, The Salk
Institute, Stroudsbourg, PA
Statement
by Major Sonnie Bates, Pilot, USAF
Statement
by Major Thomas L. Rempfer, Pilot, USAF Reserves
Statement
by Neal A. Halsey, MD, Director, Institute for Vaccine Safety, Johns
Hopkins University
- Department
of Defense Anthrax Vaccine Immunization Program
Hearing Before
the House Military Personnel Subcommittee, September 30, 1999
Opening
Statement by Chairman Buyer
Statement
by Dr. John Hamre, Deputy Secretary of Defense
Statement
by Lt. Colonel Redmond Handy, Government and Business Consulting,
Inc., USAF (Ret.)
- Medical
Readiness: Issues Concerning the Anthrax Vaccine
GAO Testimony
GAO/T-NSIAD-99-226, July 21, 1999
- Anthrax
Vaccine Adverse Reactions
Hearing Before the House Subcommittee
on National Security, Veterans' Affairs and International Relations,
July 21, 1999
Opening
Statement by Chairman Christopher Shays
Statement
by Capt. Michele L. Piel, USAF, Stevensville, MD
Statement
by Lt. Richard Rovet, USAF, Dover, DE
Statement
by Sgt. Robert Soska, USAF, Fort Stewart, GA
Statement
by Capt. Jon Richter, USAF, Annapolis, MD
Statement
by Ltc. John Jensen , Great Falls, MT
Statement
by Kwai Chan, Director, Special Studies and Evaluation Group,
National Security and International Affairs Div., General Accounting
Office
Statement
by MG Robert Claypool, Deputy Asst. Secretary for Health Operations
Policy, Dept. of Defense
Statement
by Susan Ellenberg, Director, Division of Biostatistics and
Epidemiology, Center for Biologics Evaluation and Research, Food and
Drug Administration
- Contract
Management: Observations on DOD's Financial Relationship With the
Anthrax Vaccine Manufacturer
GAO Testimony GAO/T-NSIAD-99-214,
June 30, 1999
- Medical NBC
Online
Back to Top of Page
CBW DEFENSE
- Joint Senior
Leader's Conference
Dept. of Defense, Fort Leonard Wood,
Missouri, November 2000
- Chemical and
Biological Defense: Units Better Equipped, but Training and Readiness
Reporting Problems Remain
GAO Report (GAO-01-27), November 2000
- Protecting Those
Who Serve: Strategies to Protect the Health of Deployed U.S.
Forces
Institute of Medicine, National Academy Press, 2000
- Military
Use of Drugs Not Yet Approved by the FDA for CW/BW
Defense
Richard A. Rettig, RAND Report #MR-1018/9-OSD, April 15,
1999
- "Bioweapons
Research Proliferates"
Ricki Lewis, The Scientist, Vol.
12, No. 9, April 27, 1998
- "Chemical
Alarms," from Frontline's The Last Battle of the Gulf War,
January 20, 1998
- "More
Evidence of the Mounting Biological Warfare Threat and the Inadequate
U.S. Response, " Center for Security Policy, No. 98-D 44
- United
States Army Medical Reseach Institute of Infectious Diseases
(USAMRIID):
- U.S.
Department of State Fact Sheets on Chemical-Biological Warfare
- Joint Bradford - SIPRI
Chemical and Biological Warfare Project
- Chemical and Biological
Defense Information Analysis Center (CBIAC)
The CBIAC was
established in 1986 and serves as the DoD focal point for information
related to Chemical Warfare/Chemical and Biological Defense (CW/CBD)
technology.
Last updated: 8/20/2003
Return to the CBW Resource homepage.
![Visit MIIS [ Image: MIIS Logo ]](/_navimages/logos/miis_logo_white_260x55_80percent.png "Visit MIIS [ Image: MIIS Logo ]"){kind=logo}
@CNS Updates